Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Auranofin.

P Davis

    Clinics in Rheumatic Diseases
    |August 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Auranofin offers a safer alternative to injectable gold compounds for rheumatoid disease treatment, despite a higher rate of initial inefficacy. This gold compound provides a better therapeutic to toxicity ratio, potentially allowing for earlier treatment initiation.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Survey of telephone calls to a paediatric rheumatology helpline: assessment of impact.

    Archives of disease in childhood·2009
    Same author

    Clinical experience with a glucose oxidase-containing dressing on recalcitrant wounds.

    Journal of wound care·2009
    Same author

    Introduction of a nurse-led sexual health service for HIV-positive men.

    International journal of STD & AIDS·2008
    Same author

    An experimental study of aggressive and neutral interpretative bias in opiate-dependent and opiate-abstinent men.

    Journal of psychopharmacology (Oxford, England)·2008
    Same author

    Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study.

    Kidney international·2008
    Same author

    Chaos mirror for free-space links.

    Optics letters·2007
    Same journal

    Metabolic and endocrine aspects of rheumatic disease.

    Clinics in rheumatic diseases·1986
    Same journal

    Muscle 'contractures' and the 'stiff-man' syndrome.

    Clinics in rheumatic diseases·1986
    Same journal

    Hypophosphatasia.

    Clinics in rheumatic diseases·1986
    Same journal

    Alkaptonuria.

    Clinics in rheumatic diseases·1986
    Same journal

    Diabetes mellitus and rheumatic disease.

    Clinics in rheumatic diseases·1986
    Same journal

    Musculoskeletal manifestations of primary hyperparathyroidism.

    Clinics in rheumatic diseases·1986
    See all related articles

    Area of Science:

    • Rheumatology
    • Pharmacology
    • Toxicology

    Background:

    • Chrysotherapy is a valuable treatment for rheumatoid disease, but gold compounds can be toxic.
    • Auranofin, an orally administered gold compound, was developed to improve the therapeutic to toxicity ratio.
    • Initial studies suggested auranofin offered a similar efficacy to injectable gold with improved safety.

    Purpose of the Study:

    • To evaluate the therapeutic benefit and toxicity profile of auranofin compared to injectable gold compounds.
    • To investigate the mechanism of action of auranofin in vitro and in vivo.
    • To assess the potential for auranofin in earlier treatment of rheumatoid disease.

    Main Methods:

    • Clinical studies comparing auranofin with gold thiols and other disease-remittive agents.

    Related Experiment Videos

  • Review of over 3000 patients treated with auranofin versus 465 patients treated with injectable gold.
  • In vivo and in vitro studies on auranofin's mechanism of action.

    • Main Results:

    • Auranofin demonstrated a 25-30% lower prevalence of side effects requiring withdrawal compared to injectable gold.
    • Withdrawal reasons for auranofin were often less severe, with lower rates of nephrotoxicity and hematological reactions.
    • Auranofin showed a 2-3 times higher frequency of withdrawal due to inefficacy compared to gold thiols, with a higher proportion of patients failing to respond within 3-6 months.

    Conclusions:

    • Auranofin offers a significantly improved safety margin over injectable gold compounds for rheumatoid disease treatment.
    • While auranofin may have a higher initial inefficacy rate, its comparable therapeutic profile in patients who respond and its safety make it a valuable option.
    • Further research into auranofin's mechanism of action may provide insights into rheumatoid disease pathogenesis and inform earlier treatment strategies.